75th Annual Meeting of the AUA Mid-Atlantic Section (2018)

March 1, 2018 to March 3, 2018

The 2018 Annual Meeting of the Mid-Atlantic Section will provide attendees with current updates on various urologic conditions and treatments including Urologic Cancers, Pediatrics, Geriatrics, BPH, Immunotherapy treatment as well as a review of new AUA Guidelines. This year’s program provides diverse learning formats including plenary lectures, panel discussions, moderated poster and podium sessions presented by many experts in urology. These different learning formats will allow attendees opportunities to improve their knowledge gaps and potentially change their practice patterns.

Target Audience

  • Urologist
  • APN/PA
  • Medical Student
  • Nurse
  • Research/Scientist
  • Resident

Learning Objectives

After completing this activity, the attendees will be able to:

  1. Define newly released AUA Guidelines on the topics of Stress Urinary Incontinence, Renal Mass and Localized Renal Cancer, Localized Prostate Cancer and Muscle-Invasive Bladder Cancer.
  2. Describe various established treatment paradigms and directions for clinical trials in high risk prostate cancer.
  3. Define the current state of multiparametric prostate MRI in the context of current literature
  4. List advantages and contraindications for antegrade percutaneous access and retrograde access, as well as potential complications for both procedures.
  5. Recognize symptoms of burnout syndrome and define implications of physician and staff burnout on patient outcomes.
  6. Distinguish the latest techniques, tips and innovations in percutaneous renal surgery, ureteroscopy and shock wave lithotripsy.
  7. Discuss emerging concepts, future directions, and ongoing clinical trials for prostate cancer.
  8. Review the current developments and treatments, including immunotherapy for bladder cancer.
  9. Identify the latest management and treatment strategies for high risk prostate cancer.
  10. Analyze the latest evidence on the management and treatment of non-muscle invasive bladder cancer and muscle invasive bladder cancer.
Course summary
Available credit: 
  • 17.50 AMA PRA Category 1 Credit™
  • 17.50 Non-Physician Participation
Course opens: 
Course expires: 
Event starts: 
03/01/2018 - 7:00am EST
Event ends: 
03/03/2018 - 7:00pm EST
Amelia Island, FL
United States

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Urological Associa - tion Education and Research, Inc. (AUAER) (hereafter “AUA”) and Mid-Atlantic Section of AUA (MA-AUA). The AUA is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 17.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™ . Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, bal - anced, scientifically rigorous and free of commercial bias.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, bal - anced, scientifically rigorous and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/ program director, editor, and/or Education Content Review Committee or its subgroup
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Available Credit

  • 17.50 AMA PRA Category 1 Credit™
  • 17.50 Non-Physician Participation
Please login or register to take this course.